DC Funds’s Barinthus Biotherapeutics BRNS Stock Holding History

DC Funds’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$424K	Hold	642,204	–	–	33.82%	2
2026 Q1	$365K	Hold	642,204	–	–	24.59%	3
2025 Q4	$450K	Hold	642,204	–	–	30.95%	2
2025 Q3	$803K	Hold	642,204	–	–	25.81%	3
2025 Q2	$597K	Hold	642,204	–	–	27.74%	3
2025 Q1	$625K	Hold	642,204	–	–	30.22%	2
2024 Q4	$776K	Hold	642,204	–	–	21.77%	3
2024 Q3	$764K	Hold	642,204	–	–	14.84%	3
2024 Q2	$899K	Hold	642,204	–	–	14.93%	3
2024 Q1	$1.53M	Hold	642,204	–	–	14.77%	3
2023 Q4	$2.37M	Hold	642,204	–	–	28.49%	2
2023 Q3	$1.98M	Hold	642,204	–	–	40.85%	1
2023 Q2	$1.32M	Hold	642,204	–	–	28.18%	3
2023 Q1	$1.44M	Hold	642,204	–	–	33.51%	2
2022 Q4	$1.51M	Hold	642,204	–	–	40.86%	1
2022 Q3	$2.06M	Hold	642,204	–	–	30.98%	2
2022 Q2	$2.86M	Hold	642,204	–	–	39.43%	1
2022 Q1	$3.34M	Hold	642,204	–	–	43.39%	1
2021 Q4	$7.13M	Hold	642,204	–	–	42.25%	1
2021 Q3	$10.1M	Hold	642,204	–	–	39.68%	2
2021 Q2	$10.8M	Buy	+642,204	New	+$9.5M	51.19%	1

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

GLR Partners Columbia, Maryland $215M AUM

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DC Funds's BRNS Position: Q2 2026 in Review

DC Funds held its Barinthus Biotherapeutics (BRNS) position steady in Q2 2026 at 642,204 shares worth $424K. The position accounts for 33.82% of the portfolio, ranked #2.

DC Funds first reported a position in BRNS in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.8M in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

DC Funds held 642,204 shares of Barinthus Biotherapeutics worth $424K as of Q2 2026.
DC Funds left its Barinthus Biotherapeutics share count unchanged in Q2 2026.
Barinthus Biotherapeutics made up 33.82% of DC Funds's portfolio in Q2 2026, its #2 holding.
DC Funds first reported a position in Barinthus Biotherapeutics in Q2 2021 and has held it in 21 quarters since.
DC Funds's Barinthus Biotherapeutics position peaked at $10.8M in Q2 2021.
15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on DC Funds's 13F filing for Q2 2026, filed 14 Aug 2026.